Drug intelligence / Profile preview

GSK2838505A

Development stage: Preclinical
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK2838505A is an investigational vaccine candidate developed by GSK (GlaxoSmithKline) for the prevention of infections caused by non-typeable Haemophilus influenzae (NTHi). NTHi is a significant cause of respiratory tract infections, including otitis media and exacerbations in chronic obstructive pulmonary disease. The vaccine is designed to elicit an immune response against NTHi, aiming to reduce the incidence or severity of these infections. The mechanism of action involves stimulating the immune system to recognize and respond to antigens from non-typeable Haemophilus influenzae[1][3]. Clinical trial information indicates that it has been evaluated for safety, reactogenicity, and immunogenicity[1].

Beyond the preview

Go deeper on GSK2838505A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2838505A.

Explore the full profile